Claire M. Steppan

Pfizer (United States) — United States

Medicine · Health Sciences

35h-index13.6kcitations69works19.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(16), Adipose Tissue and Metabolism(12), Adipokines, Inflammation, and Metabolic Diseases(10), COVID-19 Clinical Research Studies(9), Computational Drug Discovery Methods(9)

Publications68 total

Metabolic mapping of the human solute carrier superfamily
Molecular Systems Biology·2025· 11 citedOpen Access
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease
Journal of Medicinal Chemistry·2025· 15 cited
Drug discovery technologies–Current and future trends
Elsevier eBooks·2025
Metabolic mapping of the human solute carrier superfamily
2024· 5 citedOpen Access
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
Science Advances·2024· 34 citedOpen Access
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M<sub>4</sub> Muscarinic Acetylcholine Receptor
Journal of Medicinal Chemistry·2024· 14 citedOpen Access
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Journal of Medicinal Chemistry·2024· 59 citedOpen Access
Structural basis of the acyl-transfer mechanism of human GPAT1
Nature Structural & Molecular Biology·2022· 11 cited
BDK inhibition acts as a catabolic switch to mimic fasting and improve metabolism in mice
Molecular Metabolism·2022· 36 citedOpen Access
Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study
Antiviral Research·2022· 26 citedOpen Access
Accelerating SLC Transporter Research: Streamlining Knowledge and Validated Tools
Clinical Pharmacology & Therapeutics·2022· 16 citedOpen Access
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants
Journal of Biological Chemistry·2022· 168 citedOpen Access
Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants
2022· 26 citedOpen Access
Discovery of Small-Molecule CD33 Pre-mRNA Splicing Modulators
ACS Medicinal Chemistry Letters·2022· 16 citedOpen Access
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
Science·2021· 1.8k citedOpen Access
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Nature Communications·2021· 284 citedOpen Access
An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters
Frontiers in Pharmacology·2021· 68 citedOpen Access
An Oral SARS-CoV-2 M <sup>pro</sup> Inhibitor Clinical Candidate for the Treatment of COVID-19
2021· 23 citedOpen Access
Acoustic Ejection Mass Spectrometry for High-Throughput Analysis
Analytical Chemistry·2021· 96 citedOpen Access
A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL <sup>pro</sup> Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
Journal of Virology·2021· 139 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Stephen Noell(12), Mitchell A. Lazar(10), Annaliesa S. Anderson(10), Lisa Aschenbrenner(9), Rose Ann Ferre(8), Matthew R. Reese(8), Lorraine F. Lanyon(8), Charlotte Allerton(7), S.E. Greasley(7), Kevin Ogilvie(7), Martin Pettersson(7), Dafydd R. Owen(6), Britton Boras(6), Rhonda D. Cardin(6), Heather Eng(6), R. Scott Obach(6), K. Devendra(6), Jean G. Sathish(6), Eugene P. Kadar(5), Amit S. Kalgutkar(5)